NasdaqGS:GLUEBiotechs
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise
Earlier in January 2026, Monte Rosa Therapeutics completed a roughly US$300.00 million follow-on equity offering, including 11,125,000 common shares at US$24 each and 1,375,000 pre-funded warrants, shortly after releasing positive interim Phase 1 data for its NEK7-directed degrader MRT-8102 in inflammatory conditions.
The Phase 1 results, showing deep NEK7 degradation alongside broad reductions in inflammatory markers such as hsCRP and IL-6 with a favorable safety profile in higher...